New York Times Company Continues to Thrive Amidst Challenging Media Landscape\n\nThe New York Times Company has once again proven its resilience and strength in the media industry, reporting impressive financial results for the third quarter of 2021. The ongoing challenges faced by the media landscape, the company has continued to thrive and deliver value to its stakeholders.\n\nIn the third quarter, the company’s total revenue increased by 13.7%, reaching $426.9 million. This growth was driven by a 19.7% increase in digital advertising revenue and a 12.7% increase in subscription revenue. These results not only highlight the company’s strong fundamentals, but also demonstrate its ability to adapt and innovate in a rapidly changing industry.\n\nThe company’s success can be attributed to its strategic initiatives, including investments in digital products and services, as well as a focus on quality journalism. Its digital subscriber base has continued to grow, reaching a record high of 8.1 million subscribers. This not only reflects the company’s ability to attract and retain readers, but also its commitment to providing high-quality and trustworthy content.\n\n The economic uncertainty caused by the pandemic, the New York Times Company has remained a stable and attractive choice for investors. Its strong financial performance and strategic initiatives have positioned it as a leader in the media industry. As the company continues to evolve and innovate, it is well-positioned for long-term growth and success.\n\nIn a the New York Times Company’s impressive financial results for the third quarter of 2021 demonstrate its resilience and strength in the challenging media landscape.

ReShape Lifesciences Announces Warrant Exercise Agreement and Cost Reduction Plan\n\nReShape Lifesciences, Inc. (Nasdaq:RSLS) has recently entered into a warrant exercise agreement with an existing accredited investor to exercise outstanding warrants to purchase an aggregate of 5,382,500 shares of the company's common stock. This agreement is part of the company's efforts to reduce operating expenses in 2024 by over 40% compared to 2023.\n\nIn consideration for the immediate exercise of the existing warrants for cash, the exercising holder received new unregistered warrants to purchase up to an aggregate of 10,765,000 shares of the company's common stock. The company also agreed to reduce the exercise price of the 5,382,500 exercised warrants and 6,960,351 remaining unexercised warrants to $0.23, which is equal to the most recent closing price of the company's common stock on The Nasdaq Capital Market prior to the execution of the warrant exercise agreement.\n\nThe new warrants will become exercisable six months following issuance at an initial exercise price of $0.23 per share, which is subject to reduction as set forth in the new warrants if approved by the Company's stockholders in accordance with the rules of the Nasdaq Stock Market, and have a term of exercise equal to five and one-half years. The company also agreed to file a resale registration statement within 30 days with respect to the new warrants and the shares of common stock issuable upon exercise of the new warrants and to hold a meeting of its stockholders to seek approval of the potential reduction of the exercise price of the new warrants.\n\nThe gross proceeds to the company from the exercise of the existing warrants was approximately $1.2 million, prior to deducting placement agent fees and estimated offering expenses. The company intends to use the net proceeds for commercial growth, working capital and general corporate purposes.\n\nMaxim Group LLC acted as the exclusive warrant inducement agent and financial advisor for the transaction.\n\nReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.\n\nIn November, in response to continued pressure on the company's revenue caused by the adoption of the new ASC 606 revenue recognition standard, the company implemented a cost reduction plan to reduce operating expenses in 2024 by over 40% compared to 2023. \n\nIn a ReShape Lifesciences has announced a warrant exercise agreement and a cost reduction plan, showcasing its commitment to financial stability and growth.